Market Research & Data Review
Bexley Health · daily-range concept test, June 2026 wave
01 · Method
How the evidence was gathered
Fieldwork ran 2–26 June 2026: a 15-minute online questionnaire with 2,140 UK adults aged 25–65 who bought vitamins, minerals or supplements in the past twelve months, drawn from a nationally representative panel and weighted to the category buyer profile. Concept, framing and price were tested in randomised split cells, so no respondent saw more than one condition per design.
We reproduced Bexley’s 2025 attitudinal segmentation with 91 per cent assignment stability, so every result here reads directly against the segments the team already plans with. Twenty-four 45-minute depth interviews, spread across the five segments, sit underneath the quantitative read.
02 · The data
One concept clearly ahead, in the segments that pay
The prize first. Desk sizing puts UK retail sales of vitamins, minerals and supplements at £1.9 billion in 2025. The daily-range formats this concept competes in account for £640 million of that, and the share Bexley can credibly take by year three, on current distribution and the pricing tested here, is £38 million. The fieldwork answers whether this concept earns it.
Against the category leader, the new daily-range concept draws 44 per cent preference overall, six points shy of parity. The average hides the result. Preventative Planners, 23 per cent of buyers but an estimated 38 per cent of category value, prefer the Bexley concept by 24 points. The deficit sits with Price Anchored buyers, who were never the launch target.
The framing test is less ambiguous. Half the sample saw the range described as clinically dosed, half as naturally sourced. The clinical frame wins consideration in every segment, and most sharply where the margin lives.
Read within segment, the same split shows the gap is widest exactly where preference is already strongest: the frame decision and the targeting decision point the same way.
03 · Findings
Three findings, graded by confidence
We grade every finding by the strength of the evidence behind it. High confidence means replicated across cells and robust to weighting; moderate means a single well-powered design; directional means a signal worth funding, not yet a fact.
“Clinically dosed” is the winning frame
High confidenceThe clinical proposition drew 61 per cent consideration against 46 per cent for naturally sourced, led in all five segments, and the gap widens to 24 points among Preventative Planners. The effect holds across age, region and gender after weighting. Ref RR-02 · full-sample split test
Willingness to pay is a cliff, not a slope
Moderate confidencePriced purchase intent holds from £18 (58 per cent) to £22 (55 per cent), then falls to 39 per cent at £26. The design is monadic, one price per respondent, so the cliff is inferred across cells rather than observed within buyers, and it has not been tested in-market. Ref RR-05 · three price cells, n=712–714
A pharmacist’s voice moves the sceptics
DirectionalIn the depth interviews, 17 of 24 participants raised pharmacist recommendation unprompted as the thing that would change their mind. A small endorsement cell lifted Ingredient Sceptic consideration by 14 points, but the cell is under-powered. Treat as a hypothesis to validate, not a result to spend against. Ref RR-08 · qual + endorsement cell n=214
If it tells me the dose and shows me the evidence, I’ll pay more without thinking twice. The leafy packaging reads like it’s got something to hide.
My pharmacist saying it works would do more than any advert you could buy. That’s the only voice I trust in that aisle.
04 · Implications
What this means for the launch
Two dimensions organise the launch: how price sensitive a segment is, and how much clinical proof it needs before it buys. Mapping the five segments on those axes shows why the recommendations concentrate money where they do.
| Ref | Finding | Implication | Recommended action |
|---|---|---|---|
| RR-02 | “Clinically dosed” wins the priority segments | The launch story is efficacy, not provenance | Lead pack front and PDP copy with dose and evidence; keep botanical cues secondary |
| RR-04 | “Naturally sourced” trails in every segment | The current draft campaign leans on the weaker frame | Rebrief the creative agency before copy lock on 4 September 2026 |
| RR-05 | Willingness to pay breaks above £22 | A £24.99 debut price risks the core segment | Launch at £21.50; test £26 only inside a three-month bundle |
| RR-08 | Pharmacy endorsement may unlock sceptics | Ingredient Sceptics are reachable, not lost | Commission a 400-person validation cell before committing trade spend |
We walk the team through this readout on 16 July; the page updates in place, so this link is always the current version of the review.